SOM Biotech Licenses its First Product and Expands to the United States
Advertisement
- SOM's has granted a worldwide exclusive license to Corino Therapeutics Inc. following clinical Phase 2 testing of its lead compound SOM0266 for the treatment of TTR Amyloidosis.